[疫苗开发中的平台技术]。

IF 1.7 4区 医学 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Eberhard Hildt
{"title":"[疫苗开发中的平台技术]。","authors":"Eberhard Hildt","doi":"10.1007/s00103-025-04024-6","DOIUrl":null,"url":null,"abstract":"<p><p>Platform technologies in the narrower sense refer to approaches to vaccine development in which the vaccine is always based on a consistently identical framework and differs only in terms of the antigen. One advantage of platform technologies is their rapid adaptability for the development of a vaccine against novel pathogens or variants. Currently approved vaccines in the EU use viral vectors and mRNA as platforms. Recombinant adenoviruses (Ad), vesicular stomatitis virus (VSV), and modified vaccinia virus Ankara (MVA) serve as viral vectors. The application of mRNA-based vaccines is carried out in the form of lipid nanoparticles (LNPs). The function of the LNPs is to protect the mRNA from degradation, promote the uptake of the mRNA into the cells, and provide an adjuvant effect.</p>","PeriodicalId":9562,"journal":{"name":"Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz","volume":" ","pages":"368-377"},"PeriodicalIF":1.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950034/pdf/","citationCount":"0","resultStr":"{\"title\":\"[Platform technologies in vaccine development].\",\"authors\":\"Eberhard Hildt\",\"doi\":\"10.1007/s00103-025-04024-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Platform technologies in the narrower sense refer to approaches to vaccine development in which the vaccine is always based on a consistently identical framework and differs only in terms of the antigen. One advantage of platform technologies is their rapid adaptability for the development of a vaccine against novel pathogens or variants. Currently approved vaccines in the EU use viral vectors and mRNA as platforms. Recombinant adenoviruses (Ad), vesicular stomatitis virus (VSV), and modified vaccinia virus Ankara (MVA) serve as viral vectors. The application of mRNA-based vaccines is carried out in the form of lipid nanoparticles (LNPs). The function of the LNPs is to protect the mRNA from degradation, promote the uptake of the mRNA into the cells, and provide an adjuvant effect.</p>\",\"PeriodicalId\":9562,\"journal\":{\"name\":\"Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz\",\"volume\":\" \",\"pages\":\"368-377\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950034/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00103-025-04024-6\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00103-025-04024-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

摘要

狭义的平台技术是指疫苗开发方法,其中疫苗始终基于始终相同的框架,仅在抗原方面有所不同。平台技术的一个优势是它们对开发针对新型病原体或变体的疫苗具有快速适应性。目前欧盟批准的疫苗使用病毒载体和mRNA作为平台。重组腺病毒(Ad)、水疱性口炎病毒(VSV)和修饰的安卡拉牛痘病毒(MVA)作为病毒载体。基于mrna的疫苗以脂质纳米颗粒(LNPs)的形式应用。LNPs的功能是保护mRNA免受降解,促进mRNA进入细胞,并提供辅助作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Platform technologies in vaccine development].

Platform technologies in the narrower sense refer to approaches to vaccine development in which the vaccine is always based on a consistently identical framework and differs only in terms of the antigen. One advantage of platform technologies is their rapid adaptability for the development of a vaccine against novel pathogens or variants. Currently approved vaccines in the EU use viral vectors and mRNA as platforms. Recombinant adenoviruses (Ad), vesicular stomatitis virus (VSV), and modified vaccinia virus Ankara (MVA) serve as viral vectors. The application of mRNA-based vaccines is carried out in the form of lipid nanoparticles (LNPs). The function of the LNPs is to protect the mRNA from degradation, promote the uptake of the mRNA into the cells, and provide an adjuvant effect.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 医学-公共卫生、环境卫生与职业卫生
CiteScore
3.30
自引率
5.90%
发文量
145
审稿时长
3-8 weeks
期刊介绍: Die Monatszeitschrift Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - umfasst alle Fragestellungen und Bereiche, mit denen sich das öffentliche Gesundheitswesen und die staatliche Gesundheitspolitik auseinandersetzen. Ziel ist es, zum einen über wesentliche Entwicklungen in der biologisch-medizinischen Grundlagenforschung auf dem Laufenden zu halten und zum anderen über konkrete Maßnahmen zum Gesundheitsschutz, über Konzepte der Prävention, Risikoabwehr und Gesundheitsförderung zu informieren. Wichtige Themengebiete sind die Epidemiologie übertragbarer und nicht übertragbarer Krankheiten, der umweltbezogene Gesundheitsschutz sowie gesundheitsökonomische, medizinethische und -rechtliche Fragestellungen.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信